LimFlow SA announced that it has entered into a definitive agreement to be acquired by Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Under the terms of the agreement, LimFlow will receive $250 million in cash at closing and be eligible to receive up to $165 million in additional payments based on certain commercial and reimbursement milestones, for a total potential transaction value of up to $415 million. The transaction is expected to close in the fourth quarter of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NARI:
- Inari Medical to Present at Upcoming Investor Conferences
- Inari Medical reports Q3 EPS 5c, consensus 0c
- Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow
- Inari Medical Reports Third Quarter 2023 Financial Results
- Inari Medical price target lowered to $60 from $65 at Truist